U
Bionik Laboratories Corp.
BNKL
$0.0001
$0.000.00%
E
Sell
10/13/2023Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 10/13/2023 due to a decline in the total return index and volatility index.
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 10/13/2023 due to a decline in the total return index and volatility index.
D
Sell
8/14/2023Upgraded
Bionik Laboratories Corp. (BNKL) was upgraded to D- from E+ on 8/14/2023 due to an increase in the volatility index and total return index.
Bionik Laboratories Corp. (BNKL) was upgraded to D- from E+ on 8/14/2023 due to an increase in the volatility index and total return index.
E
Sell
7/28/2023Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 7/28/2023 due to a decline in the volatility index and total return index.
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 7/28/2023 due to a decline in the volatility index and total return index.
D
Sell
7/12/2023Upgraded
Bionik Laboratories Corp. (BNKL) was upgraded to D- from E+ on 7/12/2023 due to an increase in the volatility index and total return index.
Bionik Laboratories Corp. (BNKL) was upgraded to D- from E+ on 7/12/2023 due to an increase in the volatility index and total return index.
E
Sell
6/22/2023Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 6/22/2023 due to a decline in the solvency index, volatility index and growth index. Debt to equity increased from -3.11 to -1.33, operating cash flow declined 47.6% from -$512.8 to -$756.9, and earnings per share declined from -$0.1564 to -$0.1944.
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 6/22/2023 due to a decline in the solvency index, volatility index and growth index. Debt to equity increased from -3.11 to -1.33, operating cash flow declined 47.6% from -$512.8 to -$756.9, and earnings per share declined from -$0.1564 to -$0.1944.
D
Sell
6/20/2023Upgraded
Bionik Laboratories Corp. (BNKL) was upgraded to D- from E+ on 6/20/2023 due to an increase in the volatility index.
Bionik Laboratories Corp. (BNKL) was upgraded to D- from E+ on 6/20/2023 due to an increase in the volatility index.
E
Sell
5/31/2023Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 5/31/2023 due to a decline in the volatility index and total return index.
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 5/31/2023 due to a decline in the volatility index and total return index.
D
Sell
5/12/2023Upgraded
Bionik Laboratories Corp. (BNKL) was upgraded to D- from E+ on 5/12/2023 due to an increase in the volatility index.
Bionik Laboratories Corp. (BNKL) was upgraded to D- from E+ on 5/12/2023 due to an increase in the volatility index.
E
Sell
4/25/2023Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 4/25/2023 due to a decline in the volatility index and total return index.
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 4/25/2023 due to a decline in the volatility index and total return index.
D
Sell
4/6/2023Upgraded
Bionik Laboratories Corp. (BNKL) was upgraded to D- from E+ on 4/6/2023 due to an increase in the volatility index.
Bionik Laboratories Corp. (BNKL) was upgraded to D- from E+ on 4/6/2023 due to an increase in the volatility index.
E
Sell
3/20/2023Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 3/20/2023 due to a decline in the volatility index and total return index.
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 3/20/2023 due to a decline in the volatility index and total return index.
D
Sell
3/14/2023Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to D- from D on 3/14/2023 due to a decline in the volatility index.
Bionik Laboratories Corp. (BNKL) was downgraded to D- from D on 3/14/2023 due to a decline in the volatility index.
D
Sell
2/9/2023Upgraded
Bionik Laboratories Corp. (BNKL) was upgraded to D from E+ on 2/9/2023 due to an increase in the valuation index, growth index and total return index. Operating cash flow increased 46.32% from -$955.3 to -$512.8, total revenue increased 18.28% from $486.2 to $575.1, and EBIT increased 6.1% from -$1.11M to -$1.04M.
Bionik Laboratories Corp. (BNKL) was upgraded to D from E+ on 2/9/2023 due to an increase in the valuation index, growth index and total return index. Operating cash flow increased 46.32% from -$955.3 to -$512.8, total revenue increased 18.28% from $486.2 to $575.1, and EBIT increased 6.1% from -$1.11M to -$1.04M.
E
Sell
2/8/2023Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D on 2/8/2023 due to a noticeable decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.32 to 1.51, and the quick ratio declined from 0.86 to 0.48.
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D on 2/8/2023 due to a noticeable decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.32 to 1.51, and the quick ratio declined from 0.86 to 0.48.
D
Sell
6/13/2022Upgraded
Bionik Laboratories Corp. (BNKL) was upgraded to D from D- on 6/13/2022 due to a significant increase in the solvency index, growth index and volatility index. The quick ratio increased from 0.34 to 1.52, earnings per share increased from -$1.183 to -$0.2913, and EBIT increased 8.28% from -$1.53M to -$1.4M.
Bionik Laboratories Corp. (BNKL) was upgraded to D from D- on 6/13/2022 due to a significant increase in the solvency index, growth index and volatility index. The quick ratio increased from 0.34 to 1.52, earnings per share increased from -$1.183 to -$0.2913, and EBIT increased 8.28% from -$1.53M to -$1.4M.
D
Sell
5/5/2022Upgraded
Bionik Laboratories Corp. (BNKL) was upgraded to D- from E+ on 5/5/2022 due to an increase in the total return index.
Bionik Laboratories Corp. (BNKL) was upgraded to D- from E+ on 5/5/2022 due to an increase in the total return index.
E
Sell
4/20/2022Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 4/20/2022 due to a large decline in the solvency index, volatility index and total return index. The quick ratio declined from 0.49 to 0.34.
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 4/20/2022 due to a large decline in the solvency index, volatility index and total return index. The quick ratio declined from 0.49 to 0.34.
D
Sell
1/25/2022Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to D- from D on 1/25/2022 due to a significant decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.0791 to -$0.2148, total revenue declined 66.05% from $671.3 to $227.9, and EBIT declined 29.89% from -$801.9 to -$1.04M.
Bionik Laboratories Corp. (BNKL) was downgraded to D- from D on 1/25/2022 due to a significant decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.0791 to -$0.2148, total revenue declined 66.05% from $671.3 to $227.9, and EBIT declined 29.89% from -$801.9 to -$1.04M.
D
Sell
11/9/2021Upgraded
Bionik Laboratories Corp. (BNKL) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index and total return index.
Bionik Laboratories Corp. (BNKL) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index and total return index.
E
Sell
11/8/2021Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index and solvency index. Debt to equity increased from 1.13 to 1.34.
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index and solvency index. Debt to equity increased from 1.13 to 1.34.
D
Sell
3/1/2021Upgraded
Bionik Laboratories Corp. (BNKL) was upgraded to D from D- on 3/1/2021 due to an increase in the total return index and volatility index.
Bionik Laboratories Corp. (BNKL) was upgraded to D from D- on 3/1/2021 due to an increase in the total return index and volatility index.
D
Sell
2/12/2021Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to D- from D on 2/12/2021 due to a major decline in the growth index, valuation index and solvency index. Debt to equity increased from 0.41 to 2.97, earnings per share declined from -$0.3175 to -$1.7459, and the quick ratio declined from 0.29 to 0.15.
Bionik Laboratories Corp. (BNKL) was downgraded to D- from D on 2/12/2021 due to a major decline in the growth index, valuation index and solvency index. Debt to equity increased from 0.41 to 2.97, earnings per share declined from -$0.3175 to -$1.7459, and the quick ratio declined from 0.29 to 0.15.
D
Sell
11/16/2020Upgraded
Bionik Laboratories Corp. (BNKL) was upgraded to D from D- on 11/16/2020 due to a major increase in the growth index and volatility index. Operating cash flow increased 23.13% from -$1.63M to -$1.25M, EBIT increased 21.19% from -$1.96M to -$1.54M, and earnings per share increased from -$0.3915 to -$0.3249.
Bionik Laboratories Corp. (BNKL) was upgraded to D from D- on 11/16/2020 due to a major increase in the growth index and volatility index. Operating cash flow increased 23.13% from -$1.63M to -$1.25M, EBIT increased 21.19% from -$1.96M to -$1.54M, and earnings per share increased from -$0.3915 to -$0.3249.
D
Sell
10/8/2020Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to D- from D on 10/8/2020 due to a decline in the total return index and volatility index.
Bionik Laboratories Corp. (BNKL) was downgraded to D- from D on 10/8/2020 due to a decline in the total return index and volatility index.
D
Sell
9/23/2020Upgraded
Bionik Laboratories Corp. (BNKL) was upgraded to D from D- on 9/23/2020 due to an increase in the volatility index.
Bionik Laboratories Corp. (BNKL) was upgraded to D from D- on 9/23/2020 due to an increase in the volatility index.
D
Sell
9/8/2020Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to D- from D on 9/8/2020 due to a decline in the volatility index and total return index.
Bionik Laboratories Corp. (BNKL) was downgraded to D- from D on 9/8/2020 due to a decline in the volatility index and total return index.
D
Sell
8/21/2020Upgraded
Bionik Laboratories Corp. (BNKL) was upgraded to D from E+ on 8/21/2020 due to a noticeable increase in the growth index, valuation index and total return index.
Bionik Laboratories Corp. (BNKL) was upgraded to D from E+ on 8/21/2020 due to a noticeable increase in the growth index, valuation index and total return index.
E
Sell
8/14/2020Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 8/14/2020 due to a noticeable decline in the solvency index, valuation index and growth index. Debt to equity increased from 0.16 to 0.33, total revenue declined 72.07% from $923.3 to $257.9, and the quick ratio declined from 0.61 to 0.48.
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 8/14/2020 due to a noticeable decline in the solvency index, valuation index and growth index. Debt to equity increased from 0.16 to 0.33, total revenue declined 72.07% from $923.3 to $257.9, and the quick ratio declined from 0.61 to 0.48.
D
Sell
7/1/2020Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to D- from D on 7/1/2020 due to a large decline in the growth index, solvency index and efficiency index. Earnings per share declined from -$0.5793 to -$3.2897, net income declined 457.03% from -$2.97M to -$16.54M, and total capital declined 47.85% from $29.52M to $15.4M.
Bionik Laboratories Corp. (BNKL) was downgraded to D- from D on 7/1/2020 due to a large decline in the growth index, solvency index and efficiency index. Earnings per share declined from -$0.5793 to -$3.2897, net income declined 457.03% from -$2.97M to -$16.54M, and total capital declined 47.85% from $29.52M to $15.4M.
D
Sell
3/19/2020Upgraded
Bionik Laboratories Corp. (BNKL) was upgraded to D from D- on 3/19/2020 due to an increase in the volatility index.
Bionik Laboratories Corp. (BNKL) was upgraded to D from D- on 3/19/2020 due to an increase in the volatility index.
D
Sell
3/4/2020Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to D- from D on 3/4/2020 due to a decline in the volatility index.
Bionik Laboratories Corp. (BNKL) was downgraded to D- from D on 3/4/2020 due to a decline in the volatility index.
D
Sell
2/18/2020Upgraded
Bionik Laboratories Corp. (BNKL) was upgraded to D from D- on 2/18/2020 due to an increase in the valuation index, solvency index and volatility index.
Bionik Laboratories Corp. (BNKL) was upgraded to D from D- on 2/18/2020 due to an increase in the valuation index, solvency index and volatility index.
D
Sell
7/5/2019Upgraded
Bionik Laboratories Corp. (BNKL) was upgraded to D- from E+ on 7/5/2019 due to an increase in the efficiency index, solvency index and total return index. Debt to equity declined from 0.14 to 0, and the quick ratio increased from 0.3 to 0.61.
Bionik Laboratories Corp. (BNKL) was upgraded to D- from E+ on 7/5/2019 due to an increase in the efficiency index, solvency index and total return index. Debt to equity declined from 0.14 to 0, and the quick ratio increased from 0.3 to 0.61.
E
Sell
12/14/2018Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 12/14/2018 due to a decline in the volatility index and solvency index.
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 12/14/2018 due to a decline in the volatility index and solvency index.
D
Sell
11/29/2018Upgraded
Bionik Laboratories Corp. (BNKL) was upgraded to D- from E+ on 11/29/2018 due to an increase in the valuation index, solvency index and volatility index.
Bionik Laboratories Corp. (BNKL) was upgraded to D- from E+ on 11/29/2018 due to an increase in the valuation index, solvency index and volatility index.
E
Sell
11/14/2018Downgrade
Bionik Laboratories Corp. (BNKLD) was downgraded to E+ from D- on 11/14/2018 due to a noticeable decline in the volatility index, efficiency index and total return index. Net income declined 423.61% from -$760.7 to -$3.98M.
Bionik Laboratories Corp. (BNKLD) was downgraded to E+ from D- on 11/14/2018 due to a noticeable decline in the volatility index, efficiency index and total return index. Net income declined 423.61% from -$760.7 to -$3.98M.
D
Sell
10/30/2018Upgraded
Bionik Laboratories Corp. (BNKL) was upgraded to D- from E+ on 10/30/2018 due to a noticeable increase in the volatility index and total return index.
Bionik Laboratories Corp. (BNKL) was upgraded to D- from E+ on 10/30/2018 due to a noticeable increase in the volatility index and total return index.
E
Sell
8/30/2018Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 8/30/2018 due to a decline in the efficiency index.
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 8/30/2018 due to a decline in the efficiency index.
D
Sell
8/15/2018Upgraded
Bionik Laboratories Corp. (BNKL) was upgraded to D- from E+ on 8/15/2018 due to a large increase in the growth index, valuation index and efficiency index. Earnings per share increased from -$0.0631 to -$0.0026, net income increased 87.71% from -$6.19M to -$760.7, and total capital increased 32.05% from $20.51M to $27.09M.
Bionik Laboratories Corp. (BNKL) was upgraded to D- from E+ on 8/15/2018 due to a large increase in the growth index, valuation index and efficiency index. Earnings per share increased from -$0.0631 to -$0.0026, net income increased 87.71% from -$6.19M to -$760.7, and total capital increased 32.05% from $20.51M to $27.09M.
E
Sell
2/14/2018Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 2/14/2018 due to a significant decline in the efficiency index, valuation index and solvency index. Debt to equity increased from 0.19 to 0.4.
Bionik Laboratories Corp. (BNKL) was downgraded to E+ from D- on 2/14/2018 due to a significant decline in the efficiency index, valuation index and solvency index. Debt to equity increased from 0.19 to 0.4.
D
Sell
12/14/2017Downgrade
Bionik Laboratories Corp. (BNKL) was downgraded to D- from D on 12/14/2017 due to a decline in the growth index, efficiency index and solvency index. The quick ratio declined from 0.16 to 0.03, earnings per share declined from -$0.0232 to -$0.04, and EBIT declined 62.23% from -$2.07M to -$3.36M.
Bionik Laboratories Corp. (BNKL) was downgraded to D- from D on 12/14/2017 due to a decline in the growth index, efficiency index and solvency index. The quick ratio declined from 0.16 to 0.03, earnings per share declined from -$0.0232 to -$0.04, and EBIT declined 62.23% from -$2.07M to -$3.36M.
D
Sell
10/20/2017None
Bionik Laboratories Corp. (BNKL) was downgraded to D from U on 10/20/2017.
Bionik Laboratories Corp. (BNKL) was downgraded to D from U on 10/20/2017.
OTC PK
03/14/2025 9:51AM Eastern
Quotes delayed
